Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Funko Inc (FNKO) Price & Performance

Adaptive Biotechnologies Corp
Funko Inc

Price performance

Price movement over the last 24 hours

Key statistics

Adaptive Biotechnologies Corp vs Funko Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while Funko Inc trades at $5.3 (market cap $301.53M). The key difference: Adaptive Biotechnologies Corp is far larger — about 11× Funko Inc's market cap. Which is the better fit depends on your goals.

ADPTFNKO
Market Cap
$3.33B$301.53M
Sector
HealthConsumer Staples
52-Week High
$22.37$5.88
52-Week Low
$10.24$2.46
Enterprise Value
$3.19B$546.57M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Funko Inc

FNKO trades at $5.40, down 2.0% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth to $200.9M, beating EPS estimates, though net income remains negative. Analyst sentiment is mixed with 42.9% buy ratings, while recent news highlights strong product launches and management changes.

The outlook is cautiously optimistic given earnings beats and revenue stabilization, but profitability challenges and negative margins pose risks. Investment opportunity lies in operational turnaround and brand strength, balanced against high debt and competitive pressures in the collectibles market.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Funko Inc

Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.

Read more on FNKO